Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Mean rate of change of FEV1 over 24 months on doxycycline compared with placebo.
Rate change FVC over 24 months Change DLCO at 12 & 24 mths Change in shuttle walk distance at 12 & 24 mths Change in QOL at 12 & 24 mths Time to composite safety endpoint Number complications Number respiratory infections Adverse effects
18 Years and older (Adult, Senior)
October 5, 2009
December 2, 2015
Nottingham University Hospitals Nottingham, United Kingdom
† Study has passed its completion date and status has not been verified in more than two years.